Respinova has developed a novel non-invasive technology, Pulsehaler, that treats the core of COPD pathophysiology, small airway collapse. COPD is projected to be the world's 3rd leading cause of death by 2020, affecting 5-10% of the population ovedr 40. We are also applying our technology to improve the delivery of inhaled drugs. Both of these solutions have been proven in clinical trials, and we are currently awaiting both FDA clearance and CE mark.
Published at Tuesday, November 27, 2018 2:46 PM
Respinova attended the Innovative Enterprise Vienna conference last week after having been selected from the best Seal of Excellence candidates.
Click to watch our video presentation.
There are no organizations in the network.
